Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Oct 22, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on finding out if certain substances in the blood, called plasma biomarkers, can help diagnose a serious condition known as transplant-associated thrombotic microangiopathy (TA-TMA) in patients who have undergone blood stem cell transplants. The researchers want to see if these biomarkers can accurately predict the occurrence of TA-TMA and how well patients with certain types of blood cancers, like leukemia, might do after their transplant.

To participate, patients should be at least 18 years old, have a confirmed diagnosis of a blood disease, and be undergoing a specific type of transplant called allogeneic hematopoietic stem cell transplantation. During the study, participants will provide blood and urine samples at scheduled times after their transplant, helping researchers gather important information about TA-TMA. It’s essential for potential participants to understand that those with certain health issues, such as severe infections or organ dysfunction, may not be eligible for the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of a hematologic disease (e.g., leukemia, myelodysplastic syndromes,lymphoma) confirmed by histology or other appropriate diagnostic methods.
• • 2. undergoing allo-HSCT
• • 3. Age 14 years or older
• • 4.Informed consent must be signed before the start of the study. For participants aged 18 and above, the informed consent should be signed by the patient or their immediate family member. Considering the patient's condition, if it is not favorable for the patient to sign, the informed consent may be signed by a legal guardian or immediate family member of the patient.
• Exclusion Criteria:
• • 1. Missing or lost follow-up of key clinical data
• • 2. failure to collect plasma samples at specific time points after transplantation
• • 3. Plasma sample collection time later than the onset date of TMA
• • 4. TMA occurrence time later than 180 days after transplantation